Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024
Shuttle Pharmaceuticals (Nasdaq: SHPH) announced its CEO, Dr. Anatoly Dritschilo, will present at the 2024 ThinkEquity Conference on October 30, 2024, at 8:30 am ET. The presentation will highlight updates on the company's Phase 2 Clinical Trial of Ropidoxuridine for glioblastoma treatment and plans for Shuttle Diagnostics to develop predictive biomarkers for prostate cancer radiation therapy outcomes.
The conference will be held at the Mandarin Oriental Hotel in New York, featuring one-on-one meetings with investors. The presentation will be accessible via webcast through the company's website and the conference platform. Shuttle Pharmaceuticals focuses on improving outcomes for cancer patients treated with radiation therapy by developing radiation sensitizers.
Shuttle Pharmaceuticals (Nasdaq: SHPH) ha annunciato che il suo CEO, Dr. Anatoly Dritschilo, presenterà al 2024 ThinkEquity Conference il 30 ottobre 2024, alle 8:30 ora dell'est. La presentazione evidenzierà gli aggiornamenti sul Trial Clinico di Fase 2 di Ropidoxuridina per il trattamento del glioblastoma e i piani per Shuttle Diagnostics di sviluppare biomarcatori predittivi per gli esiti della terapia radioterapica nel cancro alla prostata.
La conferenza si terrà presso il Mandarin Oriental Hotel di New York, con incontri individuali con gli investitori. La presentazione sarà accessibile tramite webcast attraverso il sito web dell'azienda e la piattaforma della conferenza. Shuttle Pharmaceuticals si concentra sul miglioramento degli esiti per i pazienti affetti da cancro trattati con terapia radioterapica sviluppando sensibilizzatori per la radioterapia.
Shuttle Pharmaceuticals (Nasdaq: SHPH) ha anunciado que su CEO, el Dr. Anatoly Dritschilo, presentará en la 2024 ThinkEquity Conference el 30 de octubre de 2024, a las 8:30 a.m. ET. La presentación destacará las actualizaciones sobre el Ensayo Clínico de Fase 2 de Ropidoxuridina para el tratamiento del glioblastoma y los planes de Shuttle Diagnostics para desarrollar biomarcadores predictivos para los resultados de la terapia de radiación en el cáncer de próstata.
La conferencia se llevará a cabo en el Mandarin Oriental Hotel en Nueva York, con reuniones uno a uno con inversionistas. La presentación será accesible a través de un webcast a través del sitio web de la empresa y la plataforma de la conferencia. Shuttle Pharmaceuticals se centra en mejorar los resultados para los pacientes con cáncer tratados con terapia de radiación mediante el desarrollo de sensibilizadores de radiación.
셔틀 제약 (Nasdaq: SHPH)은 CEO인 아나톨리 드리치릴로 박사가 2024년 10월 30일 오전 8시 30분 동부 표준시 2024 씽크 이퀘티 컨퍼런스에서 발표할 것이라고 발표했습니다. 이 발표에서는 로피독수리딘의 교모세포종 치료를 위한 2상 임상 시험에 대한 업데이트와 셔틀 다이그노스틱스의 전립선암 방사선 치료 결과를 위한 예측 바이오마커 개발 계획이 강조됩니다.
컨퍼런스는 뉴욕의 만다린 오리엔탈 호텔에서 열리며 투자자들과의 일대일 미팅이 진행됩니다. 발표는 회사 웹사이트와 컨퍼런스 플랫폼을 통해 웹캐스트로 시청할 수 있습니다. 셔틀 제약은 방사선 치료를 받는 암 환자의 결과 개선을 위해 방사선 감수제를 개발하는 데 주력하고 있습니다.
Shuttle Pharmaceuticals (Nasdaq: SHPH) a annoncé que son PDG, Dr. Anatoly Dritschilo, présentera lors de la 2024 ThinkEquity Conference le 30 octobre 2024 à 8h30, heure de l'Est. La présentation mettra en lumière les mises à jour sur l'Essai Clinique de Phase 2 de Ropidoxuridine pour le traitement du glioblastome et les projets de Shuttle Diagnostics pour développer des biomarqueurs prédictifs pour les résultats de la thérapie par radiation dans le cancer de la prostate.
La conférence se tiendra à l'Hôtel Mandarin Oriental à New York, offrant des réunions individuelles avec des investisseurs. La présentation sera accessible via un webinaire sur le site Web de l'entreprise et la plateforme de la conférence. Shuttle Pharmaceuticals se concentre sur l'amélioration des résultats pour les patients atteints de cancer traités par radiothérapie en développant des sensibilisateurs à la radiation.
Shuttle Pharmaceuticals (Nasdaq: SHPH) hat bekannt gegeben, dass der CEO, Dr. Anatoly Dritschilo, am 30. Oktober 2024 um 8:30 Uhr ET auf der 2024 ThinkEquity Conference präsentieren wird. Die Präsentation wird Aktualisierungen zur Phase-2-Studie von Ropidoxuridin zur Behandlung von Glioblastom und die Pläne von Shuttle Diagnostics vorbringen, prädiktive Biomarker für die Ergebnisse der Strahlentherapie bei Prostatakrebs zu entwickeln.
Die Konferenz findet im Mandarin Oriental Hotel in New York statt und bietet Einzelgespräche mit Investoren an. Die Präsentation ist über einen Webcast auf der Website des Unternehmens und der Konferenzplattform zugänglich. Shuttle Pharmaceuticals konzentriert sich darauf, die Ergebnisse für Krebspatienten, die mit Strahlentherapie behandelt werden, durch die Entwicklung von Strahlensensibilisatoren zu verbessern.
- None.
- None.
GAITHERSBURG, Md., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (“RT”), today announced that its Chief Executive Officer, Dr. Anatoly Dritschilo, will present at the ThinkEquity Conference on October 30, 2024 at 8:30 am ET. The Company will also host in person one-on-one meetings with investors.
The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial strategies.
Dr. Dritschilo’s presentation will include an update on the Company's progress toward clinical and scientific milestones for its Phase 2 Clinical Trial of Ropidoxuridine for treatment of patients with glioblastoma, a deadly malignancy of the brain with no known cure. Additionally, he will provide an update on the Company’s plans for its subsidiary, Shuttle Diagnostics, Inc., to develop predictive biomarkers for prostate cancer outcomes following radiation therapy, and novel PSMA ligand for theranostic applications.
2024 ThinkEquity Conference
Conference Location: Mandarin Oriental Hotel in New York
Presentation Date: Wednesday, October 30, 2024
Presentation Time: 8:30 am ET
Presentation Webcast: The webcasted presentation can be accessed at https://wsw.com/webcast/tep25/shph/1683504 or on the Company's website at https://shuttlepharma.com/investor-relations/. The webcast will also be available for replay following the event.
1x1 Meetings: Management will be participating in in-person one-on-one meetings at the event on Wednesday, October 30, 2024. To arrange a meeting with management, please contact your ThinkEquity representative, or Lytham Partners at SHPH@lythampartners.com.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharmaceuticals is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (“RT”). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.
Shuttle Pharmaceuticals
Anatoly Dritschilo, M.D., CEO
240-403-4212
info@shuttlepharma.com
Investor Contacts
Lytham Partners, LLC
Robert Blum
602-889-9700
shph@lythampartners.com
FAQ
What will Shuttle Pharmaceuticals present at the 2024 ThinkEquity Conference?
When and where is Shuttle Pharmaceuticals (SHPH) presenting at the ThinkEquity Conference?
How can investors access Shuttle Pharmaceuticals' ThinkEquity Conference presentation?
What is the focus of Shuttle Pharmaceuticals' Phase 2 Clinical Trial?
